Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

作者：John Dormandy, B Charbonnel, D.J.A. Eckland, Erland Erdmann, Massimo Massi‐Benedetti, Ian K. Moules, Allan M. Skene, Meng H. Tan, Pierre J. Lefèbvre, Gordon Murray, Eberhard Standl, Robert G. Wilcox, Lars Wilhelmsen, John Betteridge, Kåre I. Birkeland, Alain Golay, Robert J. Heine, László Korányi, Markku Laakso, Marian Mokáň, Antanas Norkus, Valdis Pīrāgs, Toomas Podar, André Scheen, Werner A. Scherbaum, Guntram Schernthaner, Ole Schmitz, J Skrha, Ulf Smith, J Tatoń · 发表于：The Lancet · 年份：2005 · DOI：10.1016/s0140-6736(05)67528-9 · 被引用次数：4153 · 研究领域：Peroxisome Proliferator-Activated Receptors、Diabetes, Cardiovascular Risks, and Lipoproteins、Cardiovascular Function and Risk Factors